Indivior shares takes another hit

Indivior shares takes another hit

Shares in opioid addiction specialist Indivior (INDV) fell by more than a tenth – again – on the back of these half-year numbers. The group withdrew its full-year guidance earlier in July after a competitor launched a cheaper copy of its drug Suboxone into the US market. Until it can quantify just how much of that drug was sold, Indivior says it's unable to provide investors with renewed annual guidance. It has, however, promised to do so no later than the third-quarter results, which are currently scheduled for 1 November 2018.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now